Experience in Treating Multifocal Alopecia Areata in a Child with JAK Kinase Inhibitors
July 2024
in “
Medical alphabet
”
Studysummary In this case report, a 9-year-old with alopecia areata experienced full hair regrowth after six months of oral tofacitinib, with no recurrence or significant side effects for a year post-treatment. Our plain-language summary of this paper — not a Tressless recommendation.
The study presents a clinical case of treating multifocal alopecia areata in a 9-year-old child using oral tofacitinib, a JAK inhibitor. Over a 6-month treatment period, the patient experienced full recovery of hair growth on the scalp, with no significant clinical or biochemical abnormalities observed during treatment or for a year after discontinuation. Additionally, there was no recurrence of hair loss 12 months post-treatment. The findings suggest that JAK inhibitors could be effective for treating alopecia in children, though further data from randomized controlled trials are needed to ensure their safe use.
